The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Diagnosis and Management of Rheumatoid Arthritis: A Review
Abstract
IMPORTANCE: Rheumatoid arthritis (RA) occurs in about 5 per 1000 people and can lead to severe joint damage and disability. Significant progress has been made over the past 2 decades regarding understanding of disease pathophysiology, optimal outcome measures, and effective treatment strategies, including the recognition of the importance of diagnosing and treating RA early. OBSERVATIONS: Early diagnosis and treatment of RA can avert or substantially slow progression of joint damage in up to 90% of patients, thereby preventing irreversible disability. The development of novel instruments to measure disease activity and identify the presence or absence of remission have facilitated new treatment strategies to arrest RA before joints are damaged irreversibly. Outcomes have been improved by recognizing the benefits of early diagnosis and early therapy with disease-modifying antirheumatic drugs (DMARDs). The treatment target is remission or a state of at least low disease activity, which should be attained within 6 months. Methotrexate is first-line therapy and should be prescribed at an optimal dose of 25 mg weekly and in combination with glucocorticoids; 40% to 50% of patients reach remission or at least low disease activity with this regimen. If this treatment fails, sequential application of targeted therapies, such as biologic agents (eg, tumor necrosis factor [TNF] inhibitors) or Janus kinase inhibitors in combination with methotrexate, have allowed up to 75% of these patients to reach the treatment target over time. New therapies have been developed in response to new pathogenetic findings. The costs of some therapies are considerable, but these costs are decreasing with the advent of biosimilar drugs (drugs essentially identical to the original biologic drugs but usually available at lower cost). CONCLUSIONS AND RELEVANCE: Scientific advances have improved therapies that prevent progression of irreversible joint damage in up to 90% of patients with RA. Early treatment with methotrexate plus glucocorticoids and subsequently with other DMARDs, such as inhibitors of TNF, IL-6, or Janus kinases, improves outcomes and prevents RA-related disability. A treat-to-target strategy aimed at reducing disease activity by at least 50% within 3 months and achieving remission or low disease activity within 6 months, with sequential drug treatment if needed, can prevent RA-related disability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.138461 · Cited by 4,941
Self-citationSmolen, J. S., Aletaha, D., & McInnes, I. B. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30173-8 · Cited by 4,870
Self-citation2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Gregersen, P. K., Silver, J., & Winchester, R. J. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780301102 · Cited by 2,599
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Self-citationExpansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis
Scher, J. U., Sczesnak, A., Longman, R. S., Segata, N., Ubeda, C., Bielski, C., Rostron, T., Cerundolo, V., Pamer, E. G., Abramson, S. B., et al. (2013) · eLife · doi:10.7554/elife.01202 · Cited by 2,047
Nielen, M. M. J., van Schaardenburg, D., Reesink, H. W., van de Stadt, R. J., van der Horst‐Bruinsma, I. E., de Koning, M. H. M. T., Habibuw, M. R., Vandenbroucke, J. P., & Dijkmans, B. A. C. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20018 · Cited by 1,861
Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelka, K., Vollenhoven, R. V., Sharp, J., Perez, J. L., & Spencer‐Green, G. T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21519 · Cited by 1,785
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Smolen, J. S., Breedveld, F. C., Burmester, G. R., Bykerk, V., Dougados, M., Emery, P., Kvien, T. K., Navarro-Compán, M. V., Oliver, S., Schoels, M., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207524 · Cited by 1,465
Self-citationGoekoop‐Ruiterman, Y. P. M., De Vries‐Bouwstra, J. K., Allaart, C. F., Van Zeben, D., Kerstens, P. J. S. M., Hazes, J. M. W., Zwinderman, A. H., Ronday, H. K., Han, K. H., Westedt, M. L., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21405 · Cited by 1,460
Smolen, J. S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., Woodworth, T., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60453-5 · Cited by 1,399
Self-citationAbatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
Genovese, M. C., Becker, J.-C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050524 · Cited by 1,241
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis Care & Research · doi:10.1002/acr.22783 · Cited by 1,107
Emery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., & Kremer, J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092932 · Cited by 1,104
Aletaha, D., Nell, V. P., Stamm, T., Uffmann, M., Pflugbeil, S., Machold, K., & Smolen, J. S. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1740 · Cited by 1,068
Self-citationEmery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R. F., Li, N. F., Agarwal, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,060
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., del Carmen Morales, L., Reyes Gonzaga, J., Yakushin, S., Ishii, T., Emoto, K., Beattie, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608345 · Cited by 872
Bongartz, T., Nannini, C., Medina‐Velasquez, Y. F., Achenbach, S. J., Crowson, C. S., Ryu, J. H., Vassallo, R., Gabriel, S. E., & Matteson, E. L. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27405 · Cited by 864
Translocation of a gut pathobiont drives autoimmunity in mice and humans
Manfredo Vieira, S., Hiltensperger, M., Kumar, V., Zegarra-Ruiz, D., Dehner, C., Khan, N., Costa, F. R. C., Tiniakou, E., Greiling, T., Ruff, W., et al. (2018) · Science · doi:10.1126/science.aar7201 · Cited by 839
Inflammatory bone loss: pathogenesis and therapeutic intervention
Redlich, K., & Smolen, J. S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3669 · Cited by 830
Self-citationScher, J. U., Ubeda, C., Artacho, A., Attur, M., Isaac, S., Reddy, S. M., Marmon, S., Neimann, A., Brusca, S., Patel, T., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.38892 · Cited by 815
Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955–2007
Myasoedova, E., Crowson, C. S., Kremers, H. M., Therneau, T. M., & Gabriel, S. E. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27425 · Cited by 802
Felson, D. T., Smolen, J. S., Wells, G., Zhang, B., van Tuyl, L. H. D., Funovits, J., Aletaha, D., Allaart, C. F., Bathon, J., Bombardieri, S., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.149765 · Cited by 777
Self-citationSmolen, J. S., Kalden, J. R., Scott, D. L., Rozman, B., Kvien, T. K., Larsen, A., Loew-Friedrich, I., Oed, C., & Rosenburg, R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09403-3 · Cited by 771
Self-citationKremer, J. M., Genant, H. K., Moreland, L. W., Russell, A. S., Emery, P., Abud-Mendoza, C., Szechinski, J., Li, T., Ge, Z., Becker, J.-C., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-12-200606200-00003 · Cited by 715
Burmester, G. R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., Gruben, D., Wallenstein, G., Krishnaswami, S., Zwillich, S. H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61424-x · Cited by 714
Ramiro, S., Gaujoux-Viala, C., Nam, J. L., Smolen, J. S., Buch, M., Gossec, L., van der Heijde, D., Winthrop, K., & Landewé, R. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204575 · Cited by 701
Self-citationWegner, N., Wait, R., Sroka, A., Eick, S., Nguyen, K., Lundberg, K., Kinloch, A., Culshaw, S., Potempa, J., & Venables, P. J. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27552 · Cited by 683
Gabay, C., Emery, P., van Vollenhoven, R., Dikranian, A., Alten, R., Pavelka, K., Klearman, M., Musselman, D., Agarwal, S., Green, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60250-0 · Cited by 672
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 627
Self-citationDistinctions between diagnostic and classification criteria?
Aggarwal, R., Ringold, S., Khanna, D., Neogi, T., Johnson, S. R., Miller, A., Brunner, H. I., Ogawa, R., Felson, D., Ogdie, A., et al. (2015) · Arthritis Care & Research · doi:10.1002/acr.22583 · Cited by 539 · cited 2×
“However, the 2010 classification criteria, although primarily developed for identification of homogenous patient populations in clinical studies of RA, may help physicians establish a diagnosis(37,38); differences between classification and diagnosis have been summarized in a recent report.(39) The classification of R…”
Self-citation(2006) · Arthritis & Rheumatism · doi:10.1002/(issn)1529-0131 · Cited by 530
Smolen, J. S., Kay, J., Doyle, M. K., Landewé, R., Matteson, E. L., Wollenhaupt, J., Gaylis, N., Murphy, F. T., Neal, J. S., Zhou, Y., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60506-7 · Cited by 526
Self-citationMatcham, F., Scott, I. C., Rayner, L., Hotopf, M., Kingsley, G. H., Norton, S., Scott, D. L., & Steer, S. (2014) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2014.05.001 · Cited by 525
Fleischmann, R., Mysler, E., Hall, S., Kivitz, A. J., Moots, R. J., Luo, Z., DeMasi, R., Soma, K., Zhang, R., Takiya, L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31618-5 · Cited by 499
Self-citationRheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
Smolen, J. S., & Aletaha, D. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.8 · Cited by 474
Self-citationGerlag, D. M., Raza, K., van Baarsen, L. G. M., Brouwer, E., Buckley, C. D., Burmester, G. R., Gabay, C., Catrina, A. I., Cope, A. P., Cornelis, F., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200990 · Cited by 470
Self-citationPeriodontal disease and the oral microbiota in new‐onset rheumatoid arthritis
Scher, J. U., Ubeda, C., Equinda, M., Khanin, R., Buischi, Y., Viale, A., Lipuma, L., Attur, M., Pillinger, M. H., Weissmann, G., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34539 · Cited by 468
Smolen, J. S., Han, C., Bala, M., Maini, R. N., Kalden, J. R., van der Heijde, D., Breedveld, F. C., Furst, D. E., Lipsky, P. E., & ATTRACT Study Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.20982 · Cited by 462
Self-citationEmery, P., Breedveld, F. C., Dougados, M., Kalden, J. R., Schiff, M. H., & Smolen, J. S. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.4.290 · Cited by 445
Self-citationSmolen, J. S., Van Der Heijde, D. M. F. M., St.Clair, E. W., Emery, P., Bathon, J. M., Keystone, E., Maini, R. N., Kalden, J. R., Schiff, M., Baker, D., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21678 · Cited by 434
Self-citationGenovese, M. C., Fleischmann, R., Combe, B., Hall, S., Rubbert-Roth, A., Zhang, Y., Zhou, Y., Mohamed, M.-E. F., Meerwein, S., & Pangan, A. L. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31116-4 · Cited by 422
Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity
Harley, J. B., Chen, X., Pujato, M., Miller, D., Maddox, A., Forney, C., Magnusen, A. F., Lynch, A., Chetal, K., Yukawa, M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0102-3 · Cited by 406
Dougados, M., van der Heijde, D., Chen, Y.-C., Greenwald, M., Drescher, E., Liu, J., Beattie, S., Witt, S., de la Torre, I., Gaich, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210094 · Cited by 404
Van Ede, A. E., Laan, R. F. J. M., Rood, M. J., Huizinga, T. W. J., Van De Laar, M. A. F. J., Denderen, C. J. V., Westgeest, T. A. A., Romme, T. C., De Rooij, D.-J. R. A. M., Jacobs, M. J. M., et al. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1515::aid-art273>3.0.co;2-7 · Cited by 401
Silman, A. J., Newman, J., & Macgregor, A. J. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390504 · Cited by 394
Burmester, G. R., Kremer, J. M., Van den Bosch, F., Kivitz, A., Bessette, L., Li, Y., Zhou, Y., Othman, A. A., Pangan, A. L., & Camp, H. S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31115-2 · Cited by 373
Ramiro, S., Sepriano, A., Chatzidionysiou, K., Nam, J. L., Smolen, J. S., van der Heijde, D., Dougados, M., van Vollenhoven, R., Bijlsma, J. W., Burmester, G. R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210708 · Cited by 358
Self-citationSmolen, J. S., Nash, P., Durez, P., Hall, S., Ilivanova, E., Irazoque-Palazuelos, F., Miranda, P., Park, M.-C., Pavelka, K., Pedersen, R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61811-x · Cited by 357
Self-citationListing, J., Kekow, J., Manger, B., Burmester, G.-R., Pattloch, D., Zink, A., & Strangfeld, A. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204021 · Cited by 295
Genovese, M. C., Durez, P., Richards, H. B., Supronik, J., Dokoupilova, E., Mazurov, V., Aelion, J. A., Lee, S.-H., Codding, C. E., Kellner, H., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201601 · Cited by 293
van der Heijde, D. M. F. M., van Riel, P. L. C. M., Leeuwen, M. A. V., Hof, M. A. V., van Rijswijk, M. H., & van de Putte, L. B. A. (1992) · Lara D. Veeken · doi:10.1093/rheumatology/31.8.519 · Cited by 291
Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis
Crowson, C. S., Rollefstad, S., Ikdahl, E., Kitas, G. D., van Riel, P. L. C. M., Gabriel, S. E., Matteson, E. L., Kvien, T. K., Douglas, K., Sandoo, A., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211735 · Cited by 281
Chatzidionysiou, K., Emamikia, S., Nam, J., Ramiro, S., Smolen, J., van der Heijde, D., Dougados, M., Bijlsma, J., Burmester, G., Scholte, M., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210711 · Cited by 278
Self-citationBurmester, G. R., Lin, Y., Patel, R., van Adelsberg, J., Mangan, E. K., Graham, N. M. H., van Hoogstraten, H., Bauer, D., Ignacio Vargas, J., & Lee, E. B. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210310 · Cited by 272
Proposal for a new nomenclature of disease-modifying antirheumatic drugs
Smolen, J. S., van der Heijde, D., Machold, K. P., Aletaha, D., & Landewé, R. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204317 · Cited by 256
Self-citationA pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis
Vastesaeger, N., Xu, S., Aletaha, D., St Clair, E. W., & Smolen, J. S. (2009) · Rheumatology · doi:10.1093/rheumatology/kep155 · Cited by 243
Self-citationEmery, P. E., Burmester, G. R., Bykerk, V. P., Combe, B. G., Fürst, D. E., Barré, E., Karyekar, C. S., Wong, D. A., & Huizinga, T. W. J. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206106 · Cited by 241
Sokolove, J., Johnson, D. S., Lahey, L. J., Wagner, C. A., Cheng, D., Thiele, G. M., Michaud, K., Sayles, H., Reimold, A. M., Caplan, L., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38307 · Cited by 238
Pianta, A., Arvikar, S. L., Strle, K., Drouin, E. E., Wang, Q., Costello, C. E., & Steere, A. C. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93450 · Cited by 237
Westhovens, R., Taylor, P. C., Alten, R., Pavlova, D., Enríquez-Sosa, F., Mazur, M., Greenwald, M., Van der Aa, A., Vanhoutte, F., Tasset, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210104 · Cited by 236
Stolt, P., Källberg, H., Lundberg, I., Sjögren, B., Klareskog, L., & Alfredsson, L. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.022053 · Cited by 233
Dale, J. E., Stirling, A., Zhang, R., Purves, D. G., Foley, J., Sambrook, M., Conaghan, P. G., van der Heijde, D. M. F. M., McConnachie, A., McInnes, I. B., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208941 · Cited by 224
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases
Kay, J., Schoels, M. M., Dörner, T., Emery, P., Kvien, T. K., Smolen, J. S., & Breedveld, F. C. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211937 · Cited by 217
Self-citationWork disability in rheumatoid arthritis 10 years after the diagnosis.
Sokka, T., Kautiainen, H., Möttönen, T. T., & Hannonen, P. (1999) · PubMed · Cited by 216
Van Der Lubbe, P. A., Dijkmans, B. A. C., Markusse, H. M., Nässander, U., & Breedveld, F. C. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380812 · Cited by 195
Aletaha, D., Funovits, J., & Smolen, J. S. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.138693 · Cited by 194
Self-citationTocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
Burmester, G. R., Rigby, W. F., van Vollenhoven, R. F., Kay, J., Rubbert-Roth, A., Kelman, A., Dimonaco, S., & Mitchell, N. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207628 · Cited by 194
Radner, H., Neogi, T., Smolen, J. S., & Aletaha, D. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203284 · Cited by 183
Self-citationde Hair, M. J. H., van de Sande, M. G. H., Ramwadhdoebe, T. H., Hansson, M., Landewé, R., van der Leij, C., Maas, M., Serre, G., van Schaardenburg, D., Klareskog, L., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38273 · Cited by 182
Aga, A.-B., Lie, E., Uhlig, T., Olsen, I. C., Wierød, A., Kalstad, S., Rødevand, E., Mikkelsen, K., Kvien, T. K., & Haavardsholm, E. A. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204020 · Cited by 181
Smolen, J. S., Burmester, G.-R., Combe, B., Curtis, J. R., Hall, S., Haraoui, B., van Vollenhoven, R., Cioffi, C., Ecoffet, C., Gervitz, L., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31651-8 · Cited by 181
Self-citationMethotrexate therapy in rheumatoid arthritis: 15 years experience
Hoffmeister, R. T. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90477-1 · Cited by 177
Nam, J. L., Villeneuve, É., Hensor, E. M. A., Conaghan, P. G., Keen, H. I., Buch, M. H., Gough, A., Green, M. J., Helliwell, P., Keenan, A., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203440 · Cited by 166
Low, A. S. L., Symmons, D. P. M., Lunt, M., Mercer, L. K., Gale, C. P., Watson, K. D., Dixon, W. G., & Hyrich, K. L. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209784 · Cited by 158
Recent advances in the genetics of rheumatoid arthritis
Raychaudhuri, S. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328336474d · Cited by 153
Smolen, J. S., Agarwal, S. K., Ilivanova, E. P., Xu, X. L., Ye, M., Zhuang, Y., Nnane, I. P., Radziszewski, W., Greenspan, A. J., Beutler, A. M., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209831 · Cited by 144
Self-citationAletaha, D., & Smolen, J. S. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30634 · Cited by 143
Self-citationRadner, H., Smolen, J. S., & Aletaha, D. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq334 · Cited by 141
Self-citationSmolen, J. S., Ávila, J. C. M., & Aletaha, D. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200395 · Cited by 135
Self-citationGenovese, M. C., Cohen, S. B., Wofsy, D., Weinblatt, M. E., Firestein, G. S., Brahn, E., Strand, V., Baker, D. G., & Tong-Starksen, S. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.100602 · Cited by 130
Genetics of rheumatoid arthritis susceptibility, severity, and treatment response
Viatte, S., & Barton, A. C. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0630-4 · Cited by 129
Future therapeutic targets in rheumatoid arthritis?
Cheung, T. T., & McInnes, I. B. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0623-3 · Cited by 127
Emery, P. E., Bingham, C. O., Burmester, G. R., Bykerk, V. P., Furst, D. E., Xavier Mariette, A., van der Heijde, D. M. F. M., van Vollenhoven, R., Arendt, C. H., Mountian, I., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-209057 · Cited by 109
Epigenetics in the pathogenesis of RA
Ospelt, C., Gay, S., & Klein, K. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0621-5 · Cited by 107
Tan, E. M., & Smolen, J. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160792 · Cited by 103
Self-citationKaneko, Y., Atsumi, T., Tanaka, Y., Inoo, M., Kobayashi-Haraoka, H., Amano, K., Miyata, M., Murakawa, Y., Yasuoka, H., Hirata, S., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208426 · Cited by 96
Global Molecular Effects of Tocilizumab Therapy in Rheumatoid Arthritis Synovium
Ducreux, J., Durez, P., Galant, C., Toukap, A. N., den Eynde, B. J. V., Houssiau, F. A., & Lauwerys, B. R. (2013) · Arthritis & Rheumatology · doi:10.1002/art.38202 · Cited by 90
Gandolfo, S., Fabro, C., Bulfoni, M., Russi, S., Masolini, P., Quartuccio, L., Cesselli, D., & Vita, S. D. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-eular.6450 · Cited by 88
Aletaha, D., Strand, V., Smolen, J. S., & Ward, M. M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071415 · Cited by 86
Self-citationAletaha, D., Alasti, F., & Smolen, J. S. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208324 · Cited by 85
Self-citationBurmester, G. R., McInnes, I. B., Kremer, J. M., Miranda, P., Vencovský, J., Godwood, A., Albulescu, M., Michaels, M. A., Guo, X., Close, D. R., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40420 · Cited by 81
Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up
van der Heijde, D. M. F. M., van Riel, P. L. C. M., Nuver-Zwart, I. H., & van de Putte, L. B. A. (1990) · The Lancet · doi:10.1016/0140-6736(90)90771-v · Cited by 76
Scott, I. C., Seegobin, S., Steer, S. E., Tan, R., Forabosco, P., Hinks, A., Eyre, S., Morgan, A. W., Wilson, A. G., Hocking, L. J., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003808 · Cited by 64
Binder, N. B., Puchner, A., Niederreiter, B., Hayer, S., Leiss, H., Blüml, S., Kreindl, R., Smolen, J. S., & Redlich, K. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37797 · Cited by 60
Self-citationKiely, P. D. W., Walsh, D. A., Williams, R., Young, A., & for the Early Rheumatoid Arthritis Network (ERAN) (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq406 · Cited by 60
The cybernetics of TNF: Old views and newer ones
Wallach, D. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.014 · Cited by 55
The unmet need in rheumatology: Reports from the targeted therapies meeting 2017
Winthrop, K. L., Strand, V., van der Heijde, D. M. F. M., Mease, P. J., Crow, M. K., Weinblatt, M. E., Bathon, J. M., Burmester, G. R., Dougados, M., Kay, J., et al. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.08.009 · Cited by 47
Self-citationPotential Role of Bacterial Infection in Autoimmune Diseases: A New Aspect of Molecular Mimicry
Alam, J., Kim, Y. C., & Choi, Y. (2014) · Immune Network · doi:10.4110/in.2014.14.1.7 · Cited by 42
Blüml, S., Sahin, E., Saferding, V., Gonçalves‐Alves, E., Hainzl, E., Niederreiter, B., Hladik, A., Lohmeyer, T., Brunner, J. S., Bonelli, M. M., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0742-y · Cited by 33
Self-citation
Cited by
Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216655 · Cited by 2,710
Self-citationDefinition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811
Safiri, S., Kolahi, A.-A., Smith, E., Hill, C., Bettampadi, D., Mansournia, M. A., Hoy, D., Ashrafi-Asgarabad, A., Sepidarkish, M., Almasi-Hashiani, A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216515 · Cited by 1,651
Management of Rheumatoid Arthritis: An Overview
Radu, A.-F., & Bungau, S. G. (2021) · Cells · doi:10.3390/cells10112857 · Cited by 1,089
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Lin, Y.-J., Anzaghe, M., & Schülke, S. (2020) · Cells · doi:10.3390/cells9040880 · Cited by 932
Metadata
- Authors
- Aletaha, D., & Smolen, J. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2018-10-02
- Volume
- 320
- Issue
- 13
- Pages
- 1360
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2895590824
- Cited by
- 2,313
- References
- 102
- FWCI
- 106.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.